In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors.
Andrés MansisidorLaboratory of Genome Architecture and Dynamics, The Rockefeller University; New York, NY 10065, USA.ORCID 0000-0002-6607-4016 Yaron BramDivision of Gastroenterology & Hepatology, Department of Medicine, Weill Cornell Medicine; New York, NY 10065, USA.ORCID 0000-0001-9711-575X Tracy BiacoChemical Biology Program, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.
Justin RendlemanLaboratory of Genome Architecture and Dynamics, The Rockefeller University; New York, NY 10065, USA.ORCID 0000-0001-8152-7127 Sarah C FaulknerChemical Biology Program, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.ORCID 0000-0002-6085-7423 Christine LimDivision of Gastroenterology & Hepatology, Department of Medicine, Weill Cornell Medicine; New York, NY 10065, USA.
Pierre-Jacques HamardEpigenetics Research Innovation Lab, Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.ORCID 0000-0002-2484-6161 Richard P KocheEpigenetics Research Innovation Lab, Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center; New York, NY 10065, USA.ORCID 0000-0002-6820-5083 Viviana I RiscaLaboratory of Genome Architecture and Dynamics, The Rockefeller University; New York, NY 10065, USA.ORCID 0000-0003-2670-8704 Robert E SchwartzDivision of Gastroenterology & Hepatology, Department of Medicine, Weill Cornell Medicine; New York, NY 10065, USA.ORCID 0000-0002-5417-5995 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MGenetic Viral and Host Adaptations to Breach Species Barriers of HCVR01AI107301 · NIAID · PRINCETON UNIVERSITY · PI Thomas Pietschmann, Alexander Ploss · 2013 to 2026
$6.0MOptimization of the engineered 3D hepatic microenvironment enhances pluripotent stem cell derived hepatocyteR01DK121072 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHWARTZ, ROBERT E · 2020 to 2024
$2.6MPredoctoral Training in Pharmacological SciencesT32GM141949 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Kristen Elizabeth Pleil · 2021 to 2026
$2.5MCross-regulation between loop extrusion, chromatin fiber structure and chromatin-associated RNAsDP2GM150021 · NIGMS · ROCKEFELLER UNIVERSITY · PI RISCA, VIVIANA I · 2022 to 2025
$2.5MTri-Institutional PhD Program in Chemical BiologyT32GM136640 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI DEREK S TAN · 2020 to 2026
$2.4MModeling alcohol toxicity in human hepatocytesR01AA027327 · NIAAA · WEILL MEDICAL COLL OF CORNELL UNIV · PI DE JONG, YPE PETER · 2019 to 2023
$1.9MTri-Institutional PhD Program in Chemical BiologyT32GM115327 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI TAN, DEREK S · 2015 to 2019
$741kMapping the short-range chromatin architecture of the repressive epigenomeF32GM140551 · NIGMS · ROCKEFELLER UNIVERSITY · PI MANSISIDOR, ANDRES · 2021 to 2023
$205kBiochemical studies of aberrant chromatin regulation in cancerF99CA264420 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI PRESCOTT, NICHOLAS · 2021 to 2022
$94kNCI NIH HHS F99 CA264420NCI NIH HHS P30 CA008748NIAAA NIH HHS R01 AA027327NIAID NIH HHS R01 AI107301NIDDK NIH HHS R01 DK121072NIGMS NIH HHS DP2 GM150021NIGMS NIH HHS F32 GM140551NIGMS NIH HHS T32 GM115327NIGMS NIH HHS T32 GM136640NIGMS NIH HHS T32 GM141949
6 · The paper itselfAbstract
Chronic hepatitis B virus (HBV) infection is an incurable global health threat responsible for causing liver disease and hepatocellular carcinoma. During the genesis of infection, HBV establishes an independent minichromosome consisting of the viral covalently closed circular DNA (cccDNA) genome and host histones. The viral X gene must be expressed immediately upon infection to induce degradation of the host silencing factor, Smc5/6. However, the relationship between cccDNA chromatinization and X gene transcription remains poorly understood. Establishing a reconstituted viral minichromosome platform, we found that nucleosome occupancy in cccDNA drives X transcription. We corroborated these findings in cells and further showed that the chromatin destabilizing molecule CBL137 inhibits X transcription and HBV infection in hepatocytes. Our results shed light on a long-standing paradox and represent a potential new therapeutic avenue for the treatment of chronic HBV infection.
Indexed as
chromatinepigeneticsHepatitis B Virusnucleosome stabilitytranscription
Identifiers
PMID38915612
PMCPMC11195122
What OpenQuestion holds
Textmetadata
LicenceCC BY-ND
Read underepoch 390